Objective response rate in patients with FGFR2 fusions or rearrangements was 35.5%.203 Most common grade 3 or 4 toxicity was hyperphosphatemia that occurred in 12% of patients.203 In the phase II FOENIX-CCA2 trial, treatment with futibatinib, a selective, irreversible FGFR1-4 inhibitor, achieved an overall response rate (ORR) of 42% in patients with FGFR2 fusions. This evidence concerns the gene FGFR2 and hyperphosphatemia.